NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Novartis India Limited (NSE: NOVARTIND)

 
NOVARTIND Technical Analysis
3
As on 12th Aug 2022 NOVARTIND SHARE Price closed @ 707.95 and we RECOMMEND Buy for LONG-TERM with Stoploss of 706.41 & Buy for SHORT-TERM with Stoploss of 647.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

NOVARTINDSHARE Price

Open 707.00 Change Price %
High 713.80 1 Day 4.60 0.65
Low 704.00 1 Week -6.20 -0.87
Close 707.95 1 Month 40.50 6.07
Volume 12445 1 Year -119.15 -14.41
52 Week High 1048.90 | 52 Week Low 546.00
 
NSE INDIA Most Active Stocks
ZOMATO 61.75 6.65%
TATASTEEL 112.65 3.25%
IDEA 8.70 0.58%
GTLINFRA 1.40 7.69%
YESBANK 15.30 -0.65%
SUZLON 7.55 -1.95%
JPPOWER 7.50 -4.46%
ONGC 139.20 4.82%
SAIL 81.60 3.49%
IDFCFIRSTB 45.10 -0.33%
 
NSE INDIA Top Gainers Stocks
TIMESGTY 61.00 88.56%
EUROTEXIND 10.05 76.32%
SCAPDVR 12.90 30.96%
NEXTMEDIA 6.35 23.30%
WILLAMAGOR 24.90 20.00%
DFMFOODS 252.40 19.99%
EROSMEDIA 28.15 18.53%
AMDIND 71.45 17.42%
SANGHIIND 43.50 12.69%
MINDTECK 151.10 12.47%
 
NSE INDIA Top Losers Stocks
GVKPIL 5.70 -69.52%
EKC 118.80 -11.44%
PANACHE 67.75 -9.97%
BPL 69.95 -8.98%
BPL 69.95 -8.98%
IPCALAB 928.05 -8.68%
ASTERDM 216.15 -8.64%
LOKESHMACH 85.90 -8.08%
ADORWELD 801.25 -7.18%
BDL 821.65 -7.07%
 
 
NOVARTIND
Daily Charts
NOVARTIND
Intraday Charts
Whats New @
Bazaartrend
NOVARTIND
Free Analysis
 
NOVARTIND Important Levels Intraday
RESISTANCE726.83
RESISTANCE720.78
RESISTANCE717.03
RESISTANCE713.29
SUPPORT702.61
SUPPORT698.87
SUPPORT695.12
SUPPORT689.07
 
NOVARTIND Target August 2022
4th UP Target930.09
3rd UP Target847.46
2nd UP Target796.39
1st UP Target745.32
1st DOWN Target599.58
2nd DOWN Target548.51
3rd DOWN Target497.44
4th DOWN Target414.81
 
NOVARTIND Weekly Target
4th UP Target951.36
3rd UP Target875.29
2nd UP Target828.26
1st UP Target781.24
1st DOWN Target647.06
2nd DOWN Target600.04
3rd DOWN Target553.01
4th DOWN Target476.94
 
NOVARTIND Target2022
4th UP Target1870.64
3rd UP Target1519.65
2nd UP Target1302.69
1st UP Target1085.73
1st DOWN Target466.67
2nd DOWN Target249.71
3rd DOWN Target32.75
4th DOWN Target-318.24
 
 
NOVARTIND Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
 
NOVARTIND Other Details
Segment EQ
Market Capital 18732115968.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
NOVARTIND Address
NOVARTIND
 
NOVARTIND Latest News
 
Your Comments and Response on Novartis India Limited
 
NOVARTIND Business Profile
Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands. The company was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG. Address: Inspire BKC, G Block, Mumbai, India, 400051
 
© 2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service